ClinicalTrials.gg
RecruitingNCT06318533Updated Aug 13, 2026

A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

An Early Phase 1 interventional study of CAR NK cells in Autoimmune Diseases, sponsored by YANRU WANG. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by YANRU WANG · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Planned enrollment
82nd of 113
15 · median 30
Started
2024
with 25 others
Phase 1
57 of 125
40 open now
Primary completion
2026-12
later than 23 of 77 live
Registered
54th of 125
by date

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 82nd largest by planned enrollment of the 113 interventional ones that give a count, is one of 26 that started in 2024, is one of 57 in phase 1, reaches primary completion later than 23 of the 77 other live ones, and was the 54th registered.

Autoimmune Diseases

804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CAR NK cells in patients with relapsed/refractory B-cell related autoimmune diseases.15 patients are planned to be enrolled in the dose-escalation trial . The primary objective of the study is to evaluation of the safety and feasibility of CAR NK cells for the treatment of relapsed/refractory B-cell related autoimmune diseases. The secondary objective is to evaluate the effectiveness of CAR NK cells for the treatment of relapsed/refractory B-cell related autoimmune diseases. The exploratory objective is to evaluate expansion, persistence and ability to deplete B cells of CAR NK cells in patients with relapsed/refractory B-cell related autoimmune diseases.

03

Conditions studied

  • Autoimmune Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate in this clinical study and sign the Form (ICF) and are willing to follow and be able to complete all trial procedures
  2. Subjects disease status of enrolment: not complete response (CR) after standard treatment; moderately to severely active diseases
  3. Age: ≥ 18 years old and ≤ 70 years old, male or female
  4. Subjects with estimated survival > 12 weeks
  5. Adequate organs function: Serum meets relevant age/sex criteria, (AST) and alanine aminotransferase (ALT) ≤ 3 times the (ULN)
  6. performance ≤ 2
  7. (LVEF) ≥ 45%
  8. Subjects have been treated with OCS in combination with an or biologic agent for at least 2 weeks prior to enrollment

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known severe allergic reactions, , to any medications during the trial (cyclophosphamide, fludarabine, tozumabs), or subjects with a history of severe allergic reactions
  2. Subjects with one of the following genetic syndromes: Fanconi syndrome, Kostmann syndrome, Shwachman syndrome or any of the known bone marrow failure syndromes
  3. Subjects with active or uncontrolled infections requiring parenteral antimicrobials; evidence of severe active viral or bacterial infections or uncontrolled systemic fungal infections
  4. Subjects with grade III or IV heart failure ( classification)
  5. History of epilepsy or other central nervous system (CNS) diseases
  6. History of other primary malignant tumors except: cured non-melanoma skin cancer or primary cervical cancer; subjects with inactive tumors
  7. Subjects with more pronounced bleeding tendencies, such as gastrointestinal bleeding, coagulation disorders, and hypersplenism
  8. Subjects with unstable angina, symptomatic congestive heart failure or myocardial infarction within the last 6 months
  9. Females who are pregnant, lactating, or planning a pregnancy within six months
  10. Subjects who have received other clinical trial treatment within 3 months
  11. Any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    CAR NK cells

    Drug: CAR NK cells

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicity (DLTs)

    To characterize the safety of CAR NK Cells for moderate to severe autoimmune diseases.

    Time frame: within 4 weeks after infusion; 12, 24, 36 and 52 weeks after infusion

  2. Treatment Emergent Adverse Events(TEAEs)

    To characterize the safety of CAR NK Cells for moderate to severe autoimmune diseases

    Time frame: within 4 weeks after infusion; 12, 24, 36 and 52 weeks after infusion

Secondary outcomes

  1. Disease control rate of subjects

    To characterize the efficacy of CAR NK Cells for moderate to severe autoimmune diseases. Disease control is assessed according to SLEDAl 2K. Disease control rate is defined as proportion of patients with SRI-4 response: including SLEDAI 2K ≥ 4-Point improvement

    Time frame: 4, 12, 24, and 52 weeks after infusion

  2. Remission rate of subjects

    To characterize the efficacy of CAR NK Cells for moderate to severe autoimmune diseases. Remission is assessed according to SLEDAl 2K. Remission rate is defined as proportion of patients with SLEDAl 2K score= 0

    Time frame: 4, 12, 24, and 52 weeks after infusion

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 95 phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 19, 2024
StartActual
Mar 13, 2024
Primary completionEst.
Dec 13, 2026
CompletionEst.
Mar 13, 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318533
Lead sponsor
YANRU WANG
Collaborators
Rui Therapeutics Co., Ltd
Responsible party
YANRU WANG (Director, Department of Rheumatology and Immunology, Affiliated Hospital of Jiangsu University) — Sponsor-investigator
First posted
Mar 19, 2024
Start date
Mar 13, 2024
Primary completion
Dec 13, 2026 (estimated)
Completion
Mar 13, 2027 (estimated)
Last update
Aug 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor Natural Killer Cells

Start the discussion